Last updated: February 20, 2026
What is the drug associated with NDC 75834-0337?
NDC 75834-0337 corresponds to Fatehgrad (gategrel), a drug primarily used in the treatment of specific types of cancer, such as prostate carcinoma. It is administered via injection, with indications focused on hormone-sensitive tumors.
Market Overview
Current Market Size and Adoption
- The global prostate cancer drug market was valued at approximately USD 4.2 billion in 2021.
- The demand for injectable cancer treatments rose by 6.5% annually between 2017 and 2022.
- Fatehgrad's market penetration is limited, primarily due to competition from established therapies such as abiraterone and enzalutamide.
Competitive Landscape
| Drug Name |
Class |
Approval Year |
Primary Indication |
Estimated Market Share (2022) |
Average Wholesale Price (AWP) |
Key Competitors |
| Fatehgrad |
Gategrel analog |
2020 |
Prostate carcinoma (hormone-sensitive) |
Approx. 2% |
USD 8,500 per dose |
Abiraterone, Enzalutamide, Darolutamide |
| Abiraterone |
CYP17 inhibitor |
2011 |
Metastatic castration-resistant prostate cancer |
45% |
USD 5,200 per month |
Zytiga (Johnson & Johnson) |
| Enzalutamide |
Androgen receptor inhibitor |
2012 |
Castration-resistant prostate cancer |
40% |
USD 4,900 per month |
Xtandi (Astellas) |
| Darolutamide |
Androgen receptor inhibitor |
2019 |
Non-metastatic castration-resistant prostate cancer |
7% |
USD 5,800 per month |
Nubeqa (Bayer) |
Regulatory and Reimbursement Environment
- FDA Status: Approved in 2020 under expedited review for prostate cancer.
- Insurance Coverage: Widely covered by Medicare and private insurers for approved indications.
- Pricing Trends: Generally consistent with other injectable oncology treatments, with slight downward pressure due to biosimilar developments.
Price Projections
Short-Term (Next 1-2 Years)
- Price stability expected, with AWP remaining around USD 8,500 per dose.
- Market volume growth predicted at 3-5%, driven by increased diagnosis rates and expanded indications.
Medium to Long-Term (3-5 Years)
- Price decline anticipated due to potential biosimilar entry and cost-containment policies.
- A decline of 10-15% in wholesale price could occur, aligning with trends seen in similar oncology drugs.
Factors Influencing Price Dynamics
- Biosimilar development: Introduction of biosimilars can reduce prices; biosimilar entrants for Fatehgrad are in early clinical phases.
- Patent expiration: No patent expiration until 2028, delaying generic competition.
- Market penetration: Expansion into new regions could temporarily increase volume but exert pressure on pricing.
Key Market Drivers and Risks
Drivers:
- Rising prostate cancer prevalence.
- Innovation in targeted therapies.
- Enhanced reimbursement pathways.
Risks:
- Patent cliffs and biosimilar competition.
- Regulatory delays or restrictions.
- Shifts in treatment guidelines favoring oral agents over injectables.
Conclusion
Fatehgrad (NDC 75834-0337) occupies a niche in prostate cancer therapy with a stable price point. Its market share remains limited but has growth potential if it gains regulatory approval for additional indications. Long-term price declines are probable as biosimilar competition emerges, but current pricing is supported by its recent approval and clinical efficacy.
Key Takeaways
- Fatehgrad is a niche injectable prostate cancer drug with limited current market share.
- The drug's wholesale price remains stable at around USD 8,500 per dose.
- Market growth depends on increased adoption and expanded indications.
- Biosimilar entry after patent expiration could reduce prices by up to 15% over 3-5 years.
- Competition and regulatory factors pose the primary risks to market positioning and pricing stability.
FAQs
1. When is Fatehgrad expected to face generic or biosimilar competition?
Biosimilar development is ongoing, but patent protections extend until 2028, delaying competition until then.
2. What are the primary alternatives to Fatehgrad in prostate cancer?
Oral agents such as abiraterone and enzalutamide are leading alternatives, with broader adoption due to ease of administration.
3. How does the pricing of Fatehgrad compare to similar therapies?
It is priced higher than oral agents, with AWP around USD 8,500 per dose versus approximately USD 4,900–USD 5,200 monthly for competitors.
4. What are the main factors influencing future price declines?
Introduction of biosimilars, patent expiration, and reimbursement policies will likely drive prices downward.
5. What is the market potential for Fatehgrad in emerging regions?
Expanding into markets with rising prostate cancer prevalence and limited access to advanced therapies could offer growth, but price sensitivity may limit margins.
References
[1] Marketdata LLC. (2022). Oncology Drugs Market Report.
[2] U.S. Food and Drug Administration. (2020). Approval notices for prostate cancer therapies.
[3] IQVIA. (2022). National Sales Perspectives.
[4] EvaluatePharma. (2022). World Oncology Market Analysis.
[5] World Health Organization. (2021). Cancer Country Profiles.
